#mitapivat Tech News.
1 story in the last 7 days
The latest mitapivat news, distilled by AI into sharp ~100-word summaries. ByteBrief tracks mitapivat across dozens of tech sources and brings you only what matters, updated hourly. Tap any story for the full brief, or open the original source.
HealthBusiness Insider Techabout 8 hours ago
Agios Presents RISE UP Phase 3 Results at EHA 2026Agios presented 52-week RISE UP Phase 3 results for mitapivat in sickle cell disease at the EHA 2026 plenary session. The trial met its primary hemoglobin response endpoint and key secondary endpoints on hemolysis markers. Mitapivat did not reach statistical significance for reducing sickle cell pain crises or improving fatigue overall.
Summaries by ByteBrief